The invention relates to providing both fermentative and biotechnological methods for producing 3,4-methylized cinnamic acids, 3,4-methylized cinnamic acid esters, 3,4-dimethoxyphenethylamine, and 4-methylized cinnamic acid amides using a 4-O-methyltransferase, optionally in combination with further enzymes, wherein the enzymes are selected by means of metabolic engineering and operation have been adapted by targeted optimization, and compositions obtained by means of the method. The invention further relates to vector systems, recombinant microorganisms or fungi, and specific nucleic acid segments and polypeptides.

The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.

The present invention discloses a methionine adenosyltransferase (MAT) activity assay method and a kit for measuring MAT activity. A sample and relevant reagents are mixed in certain way that MAT-catalyzed reaction occurs efficiently. The reaction and the competitive ELISA that quantifies the product S-adenosylmethionine (SAM) are carried out simultaneously. The MAT activity is calculated as the amount of SAM produced per unit time. SAM is calculated through spectral absorbance of the SAM produced and comparing it to that of the standard. The method of SAM quantification is via tracer-labelled anti-SAM antibody or SAM (or SAM analog) antigen through competitive ELISA, so that the produced SAM competes with the SAM antigen for binding anti-SAM antibody. The method and the kit described in the present invention are more sensitive, accurate, reliable, straightforward, easier and faster. The method was used to measure the MAT activities of normal and cancerous liver cells.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

The present invention discloses a genetically engineered bacterium using glucose as a substrate for de novo synthesis of vanillin and an application thereof, which belongs to the technical field of gene recombination and metabolic engineering. The genetically engineered bacterium using the glucose as the substrate for de novo synthesis of vanillin disclosed by the present invention is recombinant Corynebacterium glutamicum modified by chassis microorganisms and including a vanillin synthesis module and a methyl cyclic regeneration module. The genetically engineered bacteria constructed by the present invention are safe and non-toxic, can use the glucose for de novo synthesis of natural vanillin, and is low in production cost, high in yield, and promising in application prospect.

The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.

The present specification pertains to a microorganism and/or Escherichia coli and a use thereof, wherein the microorganism and/or Escherichia coli has 3-hydroxypropionic acid or 3-hydroxypropionate (3-HP) production ability, with a foreign 3-HP production gene inserted into the genomic DNA thereof, and has a use of measuring the production ability of the inserted 3-HP production gene.

The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.

The present invention relates to a recombinant microorganism which is modified to be capable of producing diosmin and hesperidin and to the use thereof for producing diosmin and/or hesperidin.

The present invention relates to isolated polypeptides that are derived from wildtype Bacillus subtilis S-Adenosylmethionine (SAM) synthase or from a biologically active fragment thereof, wherein said isolated polypeptides comprise an amino acid sequence that, in relation to the amino acid sequence of said wildtype Bacillus subtilis SAM synthase or of the biologically active fragment thereof, comprises at least one amino acid substitution, selected from the group consisting of amino acid substitutions at positions I317 and I105. The present invention further relates to respective isolated nucleic acids, vectors, host cells, uses and methods for the production of SAM derivatives.